Antisoma Initiates Phase II Trial of AS1404 in Recurrent Ovarian Cancer
The biopharmaceutical company Antisoma has started a phase II trial of its vascular disrupting agent AS1404 in recurrent ovarian cancer, marking the third and final trial in a series evaluating AS1404 in combination with chemotherapy drugs. The trial, which will involve around 70 patients from Europe, Australia, and New Zealand, aims to determine whether patients receiving the combination of chemotherapy and AS1404 do better than those on chemotherapy alone.
Key Takeaways:
- Antisoma has initiated a phase II trial of AS1404 in recurrent ovarian cancer, with the aim of evaluating the efficacy of the combination of chemotherapy and AS1404.
- The trial will involve around 70 patients from Europe, Australia, and New Zealand, with half receiving standard chemotherapy treatment and the other half receiving the same treatment plus AS1404.
- The trial is part of a larger series of trials evaluating AS1404 in combination with chemotherapy drugs, with ongoing phase II studies in lung and prostate cancers.
- Preliminary safety and good tolerability of the AS1404-carboplatin-paclitaxel combination have been demonstrated in the ongoing lung cancer study.
- Preclinical experiments have demonstrated improved efficacy when AS1404 is used alongside paclitaxel.
Statistics:
- 70 patients will be involved in the ovarian cancer trial from Europe, Australia, and New Zealand.
- Phase II studies are ongoing in lung and prostate cancers, with the first efficacy data expected from the lung study during the second half of this year.
- Three phase I monotherapy trials including around 120 patients have been reported, with the last at ASCO 2005.
Sources:
- Antisoma plc
- COMTEX
- Buchanan Communications
- De Facto Communications
- Cancer Research U.K.
- Cancer Research Technology Limited.